Michelle Maskaly

Michelle Maskaly and Christen Harm speak with Bill Carson, President & CEO of Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC) and Kabir Nath, President & CEO of Otsuka North America Pharmaceuticals about digital medicine, mental health therapies, and creating a smooth and collaborative relationship between R&D and commercial.

Efforts to collaborate around patient engagement in every phase of product development are illustrating the growing relationship between disease advocacy groups and industry.

Brenda Snow talks to Pharm Exec about the creation of Snow Companies, the first full-service agency to bring strategic, regulatory-compliant, real-life patient stories to direct-to-patient initiatives.

Michelle Maskaly and Christen Harm talk with David Shao, CEO of Yisheng Biopharma, about what’s driving China’s exploding pharma and biotech industries, as well as the country’s push to become a global life science leader.

Pharm Exec editors sit down with Bob Ward, chairman and CEO of Eloxx Pharmaceuticals, to talk about his personal, as well as Eloxx’s, commitment to working with patient advocacy groups, how to attract talent, and how to put together a great team.

Pharm Exec editors talk with Seth Lederman, co-founder, CEO and chairman of Tonix Pharmaceuticals about how to navigate creating drugs for conditions such as PTSD and AIDS, running a business, and academia.

Event-hopping from big biz to high tech leaves same takeaway: Adaptive leadership-not innovation-is key to future synergy.

Momentum and uncertainty shape the sector's economic picture.

Pharm Exec editors Michelle Maskaly and Christen Harm speak with Raymond Sanchez, senior vice president of Global Clinical Development at Otsuka Pharmaceutical Development & Commercialization. Raymond talks about his switch from academia to clinical development, the sobering affect of seeing a drug he helped develop on the pharmacy shelf, and how he uses mindfulness to encourage and lead his team.

Michelle Maskaly and Christen Harm sit down with Editor-in-Chief Lisa Henderson and European Editor Julian Upton to discuss the industry trends featured in Pharm Exec's January 2019 issue.

Nicola Kayel, Vice President of Marketing at Salix Pharmaceuticals, speaks with Pharm Exec editors about the challenges and strategies for marketing drugs that treat embarrassing conditions, like irritable bowel syndrome. She also discusses the company’s recent plunge into virtual and augmented reality and how it plays a role in the future for healthcare professionals.

Jack Bailey, president of US pharmaceuticals for GlaxoSmithKline, talks with Christen Harm and Michelle Maskaly, about the biopharma landscape in the southeastern part of the United States, as part of Pharm Exec’s ongoing series that looks at growing biotech innovation hubs across the country. Bailey gives unmatched insights about the efforts North Carolina has put into growing, attracting, and retaining life science startups, specifically in the Raleigh-Durham area, as well as addresses challenges such as access to venture capital.

Pharm Exec examines the booming life sciences scene in southeast Virginia and Raleigh-Durham and Winston-Salem, North Carolina-and the region’s advantages in location, talent, and funding compared to the more glamour spots up north.

Pharm Exec Editorial Director Lisa Henderson and European Editor Julian Upton talk with Michelle Maskaly and Christen Harm about the magazine’s recent pharmaceutical pipeline report which was published in the November 2018 issue. Topics include cannabis, CAR-T therapy, opioids, biosimilars, and Alzheimer’s.

Global healthcare is at a crossroads when it comes to date, clinical trials, and content marketing.

Christen and Michelle talk with Mei Mei Hu, CEO of United Neuroscience about how being open to pivoting from your original plan can create a number of opportunities for an executive and their company, as well as how her executive team successfully manages a remote workforce spread across three continents. In a hilarious conversation about balancing professional and personal life, Hu also talks about how she ended up leading a spinout of her family’s life sciences business after a career in consulting, despite vowing to never be a part of the biotech world.

Michelle and Christen sit down with one of this year's Emerging Pharma Leaders, Christopher Boone, the head of real-world data and analytics center of excellence at Pfizer. We discuss what peaked Boone's interest in public health and data; the progression of how pharma and data have merged; what challenges pharma faces with data and what lies ahead; and where he got his infamous twitter handle.Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.

On Target Laboratories, CEO and Co-Founder, Martin R. Low and Philip S. Low, whose work the company is based off of and is also a co-founder of the company, join Christen Harm and Michelle Maskaly to talk about the ups and downs of commercializing research that has been previously shelved. They share how they approached another company to license the technology, why being persistent is a good thing if you truly believe the research can make a difference in the lives of patients and talk about what it’s been like to work with each other in a business, given that they Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.

While definitions for “specialty drug” vary-and distribution and pricing/reimbursement factors remain complicated-this once-niche treatment market may be poised to steer the future of prescription medicine and patient care.

How one nonprofit and its out-front leader are joining forces with industry to advance a new personalized medicine approach for cystic fibrosis patients nonsense mutations.

Learn how pharma companies are using robotics and artificial intelligence when it comes to patient care, what the funding landscape is for business in this sector and, as a member of the C-suite, find out what you need to do now to be at the forefront of this emerging technology.

Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like. Pharm Exec’s Editor-in-Chief Lisa Henderson and European Editor Julian Upton join Christen Harm and Michelle Maskaly to talk about the topic of specialty pharma, which was featured in the magazine’s September issue. They discuss the marketing, logistics, pricing, and other challenges executives in the specialty pharma industry face, as well as dive into the forces that are driving this segment of the industry and what the future will look like.

New trends report spotlights the promise and cautions for prospective life sciences dealmakers.

Though challenges in space and affordability remain, New York City is emerging as a hotspot for biotech incubators, including one unique startup based in the city’s fast-growing innovation center, whose CEO, like many C-suite veterans, made the career leap from the big pharma world to forging new discoveries in medical science.

Nancy Thornberry, CEO of Kallyope, talks with Michelle Maskaly and Christen Harm about New York City as an emerging hotspot for biotech incubators, and the challenges and opportunities related to space, location, recruitment, and funding.

Roche's Marcus Gerund is working to bring healthcare to some of the poorest areas of the world.

Jeffrey Nau is CEO of Oyster Point Pharma, a clinical stage pharmaceutical company focused on developing commercial therapies dealing with parasympathetic pathways. In a climate where oncology and rare diseases get most of the attention, Nau talks about what it’s like working on diseases that don’t get the same press, like dry eye, which is the focus of their current Phase 2 clinical trial. How this impacts raising capital and other bumps in the road he has come across. Having extensive experience with raising startup money, Nau outlines some best practices when it comes to funding.

Gil Van Bokkelen, CEO and co-founder of Athersys, talks about a pivotal moment during medical school that led him and his co-founders to eventually launch Athersys, the decision to start the company in Ohio instead of his native Northern California, and the secret to staying resilient in the c-suite, even when facing extraordinary challenges.

New Jersey is still a top pick for companies when it comes to pharma.

Korean biotech opens first U.S. headquarters in New Jersey to better control clinical trials as it looks for strategic partnerships in the U.S.